Dr. Chapman on Targeted Treatments for Non-Traditional Mutations in Melanoma

Paul B. Chapman, MD
Published: Wednesday, Jan 17, 2018



Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.

Chapman explains that non-BRAF V600 mutations are known as class II and class III mutations in melanoma. Class II mutations are similar to the BRAF V600 mutations except that they require dimerization of mutant BRAF. Ongoing clinical trials are looking at breaking apart these dimers. Class III mutations are more complicated in that they require upstream activation by RAS. Presently, MEK inhibitors are seen as the best way to target class III mutations.

However, investigators question what the best way to administer a MEK inhibitor to these patients is. Debate exists as to whether or not these inhibitors should be administered daily or periodically at high doses.
 


Paul B. Chapman, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, professor of medicine at the Weill Cornell Medical College, discusses targeted treatments for non-traditional mutations in melanoma.

Chapman explains that non-BRAF V600 mutations are known as class II and class III mutations in melanoma. Class II mutations are similar to the BRAF V600 mutations except that they require dimerization of mutant BRAF. Ongoing clinical trials are looking at breaking apart these dimers. Class III mutations are more complicated in that they require upstream activation by RAS. Presently, MEK inhibitors are seen as the best way to target class III mutations.

However, investigators question what the best way to administer a MEK inhibitor to these patients is. Debate exists as to whether or not these inhibitors should be administered daily or periodically at high doses.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x